ORIGINAL RESEARCH Upregulation of C1QTNF1 is associated with poor prognosis & immune cell infiltration in KIRC Gu L et al. Show full content
IKCS TOP 2024 Abstracts Kidney Cancer Research Highlights from 2024 IKCS Conference Show full content
ORIGINAL REVIEW Kidney function decline in cT1a patients treated with Microwave Ablation Vs PN Jessica Qiu. et al. BACKGROUND: Microwave ablation (MWA) is an emerging treatment modality for clinical T1a (cT1a) small renal masses (SRM) with studies showing it has comparable oncological outcomes to partial nephrectomy (PN). However, more research is needed on the impact of each treatment on kidney function decline. .... Show full content
ORIGINAL REVIEW Minimally Invasive Kidney Surgery: Emerging Oncological Concerns Fletcher SA et al. Show full content
ESMO 2024 Abstract Kidney Cancer Research Highlights from 2024 ESMO Annual Meeting Yasser Ged and Nirmish Singla. Show full content
ORIGINAL REVIEW The Prognostic Value of Proteinuria Prior to Surgical Treatment of RCC Yong C. et al. Show full content
CASE STUDY CN Following Immunotherapy for mRCC and IVC Tumor Thrombus Fletcher SA et al. Show full content
ASCO 2024 Summary Kidney Cancer Research Highlights from 2024 ASCO Annual Meeting Yasser Ged and Nirmish Singla. Show full content
ORIGINAL REVIEW Living with Metastatic Renal Cell Carcinoma: Survivorship Needs in the Combination Therapy Era Nikita V. Baclig et al. Show full content
GU24 Summary Kidney Cancer Research Highlights from ASCO-GU 2024 Meeting Yasser Ged and Nirmish Singla. Show full content
ORIGINAL RESEARCH Molecular and Immune Landscape of Fumarate Hydratase-mutated RCC Bayan Al-Share et al. Show full content
COMMENTARY Commentary on "Molecular and Immune Landscape of Fumarate Hydratase-mutated RCC" Nirmish Singla, MD. Show full content
ORIGINAL REVIEW Cytoreductive Nephrectomy for mRCC – Current Concepts and Contentions in the Era of ICI Shapiro DD et al. Show full content
ORIGINAL REVIEW Current perspective on the impact of endogenous retroviruses in ccRCC Gessner KH et al Show full content
REVIEW ARTICLE An Opportunity to Study Mechanisms of Palliative Care by Integrating into Management of RCC Patel HV et al Show full content
Editorial Perspective HIF Pathway Inhibition hold much promise and Point Toward an expanding RCC Armamentarium Senthil Pazhanisamy Show full content
KCJ Medical Intelligence The latest breakthroughs and research updates in the renal cancer space -- Show full content
CASE STUDY An Opportunity to Study Mechanisms of Palliative Care by Integrating into Management of RCC Roy Elias, Yasser Ged, Nirmish Singla Show full content
RECOMMENDED ABSTRACTS Recommended Abstracts from ASCO23 in Renal Cancers Robert A. Figlin Show full content
CASE STUDY Ex-Vivo Partial Nephrectomy in a Solitary Kidney Rebecca A. Campbell et al. Show full content
CASE STUDY Robotic-assisted cytoreductive partial nephrectomy for met-sarcomatoid RCC following dramatic response to combination IO therapy in a young female Bhanji Y et al Show full content
ASCO23 coverage Kidney Cancer Updates from the 2023 ASCO Annual Meeting in Chicago. Roy Elias, Yasser Ged, Nirmish Singla Show full content
RECOMMENDED ABSTRACTS Recommended Abstracts from ASCO23 in Renal Cancers Robert A. Figlin Show full content
CASE STUDY Successful Management of Metastatic Chromophobe RCC with NIVO + IPI Ravindra A, Dahmoush L, Rohan Garje R* Show full content
REVIEW ICIs in RCC: Examining the Impact of Nutritional Status, Inflammation, & Body Composition Edouard H. Nicaise et al Show full content
ASCO GU23 coverage Abstracts Highlight Progress in the Fight Against Kidney Cancer - GU ASCO 2023 Arpita Desai, MD Show full content
Editor's Memo Practice-Changing Cancer Trials Take Center Stage at the ASCO GU 2023 Robert A. Figlin Show full content
ORIGINAL RESEARCH Exploring Treatment-Free Survival with Checkpoint Inhibitors Grayce N. Selig, MD1 Christopher J. Hoimes, DO,2 Joe Bible, PhD,3 Daniel J. George, MD,2 Michael R. Harrison, MD2 Show full content
Editorial Perspective A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies Robert A Figlin, MD, FACP1 , Senthil Pazhanisamy, PhD Show full content
Editor's Memo 2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy Robert. A. Figlin, MD Show full content
ESMO22 ABSTRACTS ESMO22 - Recommended Abstracts in Renal Cancers Robert A. Figlin, MD Show full content
Expert Roundtable Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in aRCC Motzer RJ, Choueiri TK, Albiges L & Figlin RA Show full content
Original Contribution Comparison of Papillary Renal Cell Carcinoma Type 1 and Type 2 Paquin M, Fasolino T, Bible J, Steck MB, Williams J. Show full content
Review Article Engineered T-Cell Therapy: The Next Direction for RCC Immuno-oncology? JJ H. Zhang, Neal A. Patel, Alexandra Drakaki, Allan J. Pantuck,* Show full content
ASCO22 Session ASCO22 - RECOMMENDED ABSTRACTS IN KIDNEY CANCER Robert A. Figlin, MD Show full content
ASCO22 Meeting HIGHLIGHTS Kidney Cancer Research Highlights from ASCO 2022 Yasser Ged, Nirmish Singla Show full content
Original Research The Latinx Disparity in Surgery for Kidney Cancer: Data from The South Texas Region Dursun F, Patel SR.....Kaushik D Show full content
Roundtable Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma Nizar M. Tannir, Arlene O. Siefker-Radtke, Robert A. Figlin, Show full content
Review Article Moving Beyond BMI – Developments in Body Composition and Muscle Measurement in RCC Dzimitrowicz H.....Harrison MR
ASCO GU22 Coverage Kidney Cancer Research Highlights from ASCO GU 2022 Meeting Yasser Ged, Nirmish Singla. Show full content
Original Contribution Radiological Correlates of pT3a Kidney Cancer: Importance of Irregular Tumor Sinus Border Yunlin Ye*, Diego Aguilar Palaciosa, Rebecca Campbell et al. Show full content
COMMENTARY How Can We Predict pT3a Kidney Cancer and What Does It Mean? Nirmish Singla, MD. Show full content
IKCS 2021 COVERAGE IKCS 2021: Moving Kidney Cancer Care Forward Marc Matrana, MD, FACP Show full content
TOP ABSTRACTS IKCS 2021: TOP ABSTRACTS Robert A Figlin, MD TOP ABSTRACTS Top Abstracts from IKCS 2021 conference have been picked by Dr. Robert A Figlin, MD. ...........Show full content
Original Contribution Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial Susan Halabi, Qian Yang, Andrea Carmack, Andrew J. Armstrong MD et al. Show full content
Expert Q&A The Pathway of Belzutifan, from clinical trials to clinical practice: A conversation with Dr. Ramaprasad Srinivasan, MD, PhD Show full content
Review Article The Current and Evolving Therapeutic Paradigm in the Management of Metastatic Renal Cell Carcinoma Thomas Hutson, MD, Robert A. Figlin, MD, FACP Show full content
KCJ Editor's Memo Robert A. Figlin MD Novel Combination Therapies Shake Up the Spectrum of Renal Cancer Treatment.....Show full content
Original Contribution Resource-efficient pooled sequencing expands translational impact in solid tumors Renzo G. DiNatale et al. Show full content
Roundtable Monograph Changes, Challenges and Opportunities in Cancer Care During the COVID-19 Era and Beyond Robert J. Motzer, MD, Eric A. Jonasch, MD,Bradley A. McGregor, MD, Robert A. Figlin, MD, FACP Show full content
KCJ REVIEW ARTICLE Dissecting the role of lymphadenectomy in the management of renal cell carcinoma:past, present, and future Alain Kaldany, Zev R. Leopold, Juliana E. Kim, Hiren V. Patel, Arnav Srivastava, Alexandra L.Tabakin, Eric A. Singer AbstractLymph node involvement in renal cell carcinoma (RCC) portends a poor prognosis. However, the role of lymph node dissection (LND) at the time of tumor resection is not fully understood. Given the paucity of high-quality evidence supporting or refuting the routine use of LND in RCC, further research is needed to shed light on this important topic........Show full content
ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)
ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)
